CYFRA21-1和SCCAg在宫颈癌诊断和放疗疗效评价中的作用

王新华; 桂霞; 董占飞

doi:10.13406/j.cnki.cyxb.2010.09.035

您当前的位置：

首页 >

文章列表页 >

CYFRA21-1和SCCAg在宫颈癌诊断和放疗疗效评价中的作用

基础研究 | 更新时间：2024-01-17

- CYFRA21-1和SCCAg在宫颈癌诊断和放疗疗效评价中的作用
- The value of serum CYFRA21-1 and SCCAg in diagnosis of cervical cancer patients treated with radiation therapy
- 重庆医科大学学报 2010年35卷第9期页码：1365-1367
- 作者机构：
  
  1. 新疆医科大学附属肿瘤医院核医学科
  2. 新疆医科大学附属肿瘤医院输血科
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.2010.09.035
  中图分类号： R737.33
- 纸质出版日期：2010，
扫描看全文
[1]王新华,桂霞,董占飞.CYFRA21-1和SCCAg在宫颈癌诊断和放疗疗效评价中的作用[J].重庆医科大学学报,2010,35(09):1365-1367.

WANG Xin-hua, et al. The value of serum CYFRA21-1 and SCCAg in diagnosis of cervical cancer patients treated with radiation therapy[J]. Journal of Chongqing Medical University, 2010,35(9):1365-1367.
[1]王新华,桂霞,董占飞.CYFRA21-1和SCCAg在宫颈癌诊断和放疗疗效评价中的作用[J].重庆医科大学学报,2010,35(09):1365-1367. DOI： 10.13406/j.cnki.cyxb.2010.09.035.

WANG Xin-hua, et al. The value of serum CYFRA21-1 and SCCAg in diagnosis of cervical cancer patients treated with radiation therapy[J]. Journal of Chongqing Medical University, 2010,35(9):1365-1367. DOI： 10.13406/j.cnki.cyxb.2010.09.035.

摘要

目的:探讨与宫颈癌相关的两种肿瘤标记物CYFRA21-1和SCCAg在宫颈癌诊断和放疗疗效评价中的作用。方法:采用放射免疫分析法及酶联免疫吸附法分别检测70例宫颈癌患者放疗前后、30例宫颈上皮内瘤样病变（Cervical intraepithelial neoplasia

CIN）患者及30名健康妇女血清CYFRA21-1、SCCAg。结果:①宫颈癌Ⅱ、Ⅲ-Ⅳ患者CYFRA21-1、SCCAg水平高于宫颈癌Ⅰ、CIN组和健康对照组

差异有显著性（P<0.05）。②宫颈癌患者CYFRA21-1、SCCAg阳性检出率随临床分期的进展而增高

Ⅲ-Ⅳ的阳性检出率高于Ⅰ、Ⅱ期

差异有显著性（P<0.05）;宫颈癌Ⅱ期的阳性检出率高于Ⅰ期

差异有显著性（P<0.05）。③CYFRA21-1、SCCAg升高用于宫颈癌诊断的敏感度分别为44.29%、42.86%

两者联合检测的敏感度达61.43%。④放疗后

血清中CYFRA21-1和SCCAg水平均明显下降。结论:CYFRA21-1和SCCAg两种肿瘤标记物在宫颈癌中均有一定的应用价值

特别是对宫颈癌患者的诊断预后及放疗效果的评价具有重要价值。

Abstract

Objective:To investigate the clinical significance of CYFRA21-1 and squamous cell carcinoma antigen(SCCAg) in diagnosis of cervical cancer patients treated with radiation therapy.Methods:CYFRA21-1 were measured by immunoradioasseey.SCCAg were measured by Enzyme-linked Immunosorbent Assay.30 healthy females and 30 cervical intraepithelial neoplasia and 70 patients with cervical cancer before and after radiation therapy were measured.Result:①The serum levels of CYFRA21-1 and SCCAg in cervical cancer Ⅱ

Ⅲ-Ⅳ were significant higher than Ⅰ

cervical intraepithelial neoplasis(CIN)and healthy females(P<0.05).②The positive rate of CYFRA21-1 and SCCAg in patients with cervical cancer increased with advance of the clinical stages.The positive rate of Ⅲ-Ⅳ were significant higher than Ⅰ

Ⅱ cervical cancer.(P<0.05);and the positive rate of II is higher than Ⅰ(P<0.05).③The sensitivity of CYFRA21-1 and SCCAg was 44.29%

42.86%.The sensitivity combination measuring of CYFRA21-1 and SCCAg was 61.43% in diagnosis of cervical cancer.④The serum levels of CYFRA21-1 and SCCAg decreased significantly at the end of radiation therapy.Conclusions:There were specifically clinical application value of these two tumor markers for diagnosis

Specially in monitoring the outcome of patients and curative effecting of radiation therapy.

关键词

宫颈癌CYFRA21-1SCCAg放疗

Keywords

cervical cancerCYFRA21-1SCCAgRadiation therapy

references

浏览量

157

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

基于图神经网络改进宫颈癌筛查系统与宫颈细胞DNA定量在高危型HPV阳性患者中的比较

人工智能技术在宫颈癌筛查和精准临床诊疗中的研究进展

CXCL10/CCL2 信号通路介导肿瘤微环境中宫颈癌的发展

SMYD2在宫颈癌中的表达变化及意义

鼻咽癌放疗后改变与复发的CT鉴别